循环肿瘤细胞在结直肠癌中的应用
Application of Circulating Tumor Cells in Colorectal Cancer
摘要: 具有高特异性和敏感性的新的诊断和预后生物标志物是目前管理结直肠癌患者的一个重要的需求。循环肿瘤细胞(Circulating tumor cells, CTC)被认为是肿瘤复发的原因，得益于分子生物学技术的发展，其正在逐步应用于恶性肿瘤的临床诊疗中。它具有微创、可重复的优点，可在结肠直肠癌患者的筛查和诊断、预测复发和转移、监测微小残留病和化疗耐药等方面发挥重要作用。尽管有这些优势，但它并没有包括在临床指南中，仍有一些实际问题需要解决。该文的目的是对已进行的临床试验进行总结，进一步理解其在结直肠癌患者管理中的作用。
Abstract: New diagnostic and prognostic biomarkers with high specificity and sensitivity are currently an important need in the management of patients with colorectal cancer. Circulating tumor cells (CTC) are considered to be the cause of tumor recurrence. Thanks to the development of molecular biology technology, CTC has been gradually applied in the clinical diagnosis and treatment of malignant tumors. It has the advantages of minimally invasive and repeatable, and can play an important role in screening and diagnosis of colorectal cancer patients, predicting recurrence and metastasis, monitoring minimal residual disease and chemotherapy resistance. Despite these advantages, they are not included in clinical guidelines and there are practical issues that need to be addressed. The purpose of this article is to summarize the clinical trials that have been conducted and to further understand its role in the management of patients with colorectal cancer.
文章引用：廖亮亮, 高永建, 宋德锋, 冯野. 循环肿瘤细胞在结直肠癌中的应用[J]. 临床医学进展, 2022, 12(3): 1629-16533. https://doi.org/10.12677/ACM.2022.123234

参考文献

[1] Nelson, N.J. (2010) Circulating Tumor Cells: Will They Be Clinically Useful? JNCI: Journal of the National Cancer Institute, 102, 146-148. [Google Scholar] [CrossRef] [PubMed]
[2] Vasseur, A., Kiavue, N., Bidard, F.C., et al. (2021) Clinical Utility of Circulating Tumor Cells: An Update. Molecular Oncology, 15, 1647-1666. [Google Scholar] [CrossRef] [PubMed]
[3] Huang, L., Yang, Y., Yang, F., et al. (2018) Functions of EpCAM in Physiological Processes and Diseases (Review). International Journal of Molecular Medicine, 42, 1771-1785. [Google Scholar] [CrossRef] [PubMed]
[4] Maetzel, D., Denzel, S., Mack, B., et al. (2009) Nuclear Signalling by Tumour-Associated Antigen EpCAM. Nature Cell Biology, 11, 162-171. [Google Scholar] [CrossRef] [PubMed]
[5] Gorges, T.M., Tinhofer, I., Drosch, M., et al. (2012) Circulating Tumour Cells Escape from EpCAM-Based Detection Due to Epithelial-to-Mesenchymal Transition. BMC Cancer, 12, Article No. 178. [Google Scholar] [CrossRef] [PubMed]
[6] Yokobori, T., Iinuma, H., Shimamura, T., et al. (2013) Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis. Cancer Research, 73, 2059-2069. [Google Scholar] [CrossRef] 
[7] Sugimachi, K., Yokobori, T., Iinuma, H., et al. (2014) Aberrant Expression of Plastin-3 via Copy Number Gain Induces the Epithelial-Mesenchymal Transition in Circulating Colorectal Cancer Cells. Annals of Surgical Oncology, 21, 3680-3690. [Google Scholar] [CrossRef] [PubMed]
[8] Armstrong, A.J., Marengo, M.S., Oltean, S., et al. (2011) Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research, 9, 997-1007. [Google Scholar] [CrossRef] 
[9] Ning, Y., Hanna, D.L., Zhang, W., et al. (2015) Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Molecular Cancer Therapeutics, 14, 2401-2408. [Google Scholar] [CrossRef] 
[10] Zhao, R., Cai, Z., Li, S., et al. (2017) Expression and Clinical Relevance of Epithelial and Mesenchymal Markers in Circulating Tumor Cells from Colorectal Cancer. Oncotarget, 8, 9293-9302. [Google Scholar] [CrossRef] [PubMed]
[11] Matsusaka, S., Suenaga, M., Mishima, Y., et al. (2011) Circulating Tumor Cells as a Surrogate Marker for Determining Response to Chemotherapy in Japanese Patients with Metastatic Colorectal Cancer. Cancer Science, 102, 1188-1192. [Google Scholar] [CrossRef] [PubMed]
[12] Aggarwal, C., Meropol, N.J., Punt, C.J., et al. (2013) Relationship among Circulating Tumor Cells, CEA and Overall Survival in Patients with Metastatic Colorectal Cancer. Annals of Oncology, 24, 420-428. [Google Scholar] [CrossRef] [PubMed]
[13] Sastre, J., Vidaurreta, M., Gómez, A., et al. (2013) Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients with Metastatic Colorectal Cancer Treated with Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer, 12, 280-286. [Google Scholar] [CrossRef] [PubMed]
[14] van Dalum, G., Stam, G.J., Scholten, L.F., et al. (2015) Importance of Circulating Tumor Cells in Newly Diagnosed Colorectal Cancer. International Journal of Oncology, 46, 1361-1368. [Google Scholar] [CrossRef] [PubMed]
[15] Coumans, F.A., Ligthart, S.T., Uhr, J.W., et al. (2012) Challenges in the Enumeration and Phenotyping of CTC. Clinical Cancer Research, 18, 5711-5718. [Google Scholar] [CrossRef] 
[16] Tsai, W.S., Chen, J.S., Shao, H.J., et al. (2016) Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Scientific Reports, 6, Article No. 24517. [Google Scholar] [CrossRef] [PubMed]
[17] Krebs, M.G., Renehan, A.G., Backen, A., et al. (2015) Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 14, 115-122.
[18] Aranda, E., Viéitez, J.M., Gómez-España, A., et al. (2020) FOLFOXIRI Plus Bevacizumab versus FOLFOX Plus Bevacizumab for Patients with Metastatic Colorectal Cancer and ≥3 Circulating Tumour Cells: The Randomised Phase III VISNÚ-1 Trial. ESMO Open, 5, e944.
[19] Fan, T., Zhao, Q., Chen, J.J., et al. (2009) Clinical Significance of Circulating Tumor Cells Detected by an Invasion assay in Peripheral Blood of Patients with Ovarian Cancer. Gynecologic Oncology, 112, 185-191.
[20] Galizia, G., Gemei, M., Orditura, M., et al. (2013) Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 17, 1809-1818. [Google Scholar] [CrossRef] [PubMed]
[21] Mamdouhi, T., Twomey, J.D., McSweeney, K.M., et al. (2019) Fugitives on the Run: Circulating Tumor Cells (CTCs) in Metastatic Diseases. Cancer and Metastasis Reviews, 38, 297-305. [Google Scholar] [CrossRef] [PubMed]
[22] Marcuello, M., Vymetalkova, V., Neves, R., et al. (2019) Circulating Biomarkers for Early Detection and Clinical Management of Colorectal Cancer. Molecular Aspects of Medicine, 69, 107-122. [Google Scholar] [CrossRef] [PubMed]

为你推荐